Nabriva Therapeutics plc (NBRV) shares went up 13.79% in after-hours on Thursday, August 05, 2021, and closed the daily trading at $1.32 per share. However, in the regular trading session of Thursday, NBRV’s stock lost 4.13%. The stock volume remained 1.02 million shares, which was lower than the average daily volume of 4.79 million shares within the past 50 days. NBRV shares have fallen 85.95% over the last 12 months, and they have moved up 4.50% in the past week. Over the past three months, the stock has lost 22.15%, while over the past six months, it has shed 60.54%.
NBRV recent financial results announcement
On August 05, 2021, Nabriva Therapeutics plc (NBRV) announced its financial results for the three months ended June 30, 2021.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
- Are You Looking for Dividend Paying Stocks? Here are the Best Buys in 2021
- Two Promising Pet Stocks for Investment as we Head 2021
Q2 2021 financial highlights
- NBRV reported revenue of $8.2 million for Q2 2021 compared to $0.5 million for Q2 2020.
- The cost of product sales was $3.6 million for Q2 2021 compared to $0.4 million for Q2 2020.
- Total operating expenses were $19.6 million for Q2 2021 compared to$14.9 million for Q2 2020.
- It suffered a net loss of $11.8 million or a net loss of $0.29 per basic and diluted share in Q2 2021 compared to a $15.4 million loss or net loss of $1.37 per basic and diluted share for Q2 2020.
- The Company had cash and cash equivalents of $61.3 million on June 30, 2021.
NBRV inducement grants
On August 03, 2021, Nabriva Therapeutics plc (NBRV) announced that it has granted non-statutory stock options to purchase an aggregate of 10,500 ordinary shares of Nabriva Therapeutics as an inducement to three newly-hired employees. These grants were awarded according to the Nasdaq inducement grant exception as a component of new hire employment compensation.
Earlier on July 09, 2021, the company also granted non-statutory stock options to purchase an aggregate of 2,250 ordinary shares of Nabriva Therapeutics as an inducement to a newly hired employee.
NBRV agreement with Hercules Capital
On June 03, 2021, Nabriva Therapeutics plc (NBRV) signed an agreement with Hercules Capital, Inc to extend principal payments under its existing loan agreement until at least January 1, 2022. Repayments of outstanding principal amounts under the company’s debt facility with Hercules were scheduled to begin on July 1, 2021. Terms of the amended agreement provide for an initial six-month extension to January 1, 2022, with the ability to delay the principal debt repayments until July 1, 2022, upon achievement of certain financing and product revenue milestones.
Changes to NBRV Board of Directors
On June 02, 2021, Dr. George Talbot notified the company of his decision not to stand for re-election to the Board of Directors. Dr. Talbot is expected to continue his service on the Board of Directors until the conclusion of his term at the 2021 Annual General Meeting of Shareholders. The company also appointed Dr. Mark Corrigan and Lisa Dalton to the Company’s Board of Directors.
The stock turnaround in the after-hours on Thursday after the announcement of financial results which improved significantly. We are expecting it to continue its positive momentum on Friday as well.